Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Slides:



Advertisements
Similar presentations
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Advertisements

The POSITIVE study A large international research effort coordinated by International Breast Cancer Study Group (IBCSG) worldwide ALLIANCE for Clinical.
The Nurse View: Management of Pancreatic Cancer
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Evolving Paradigms in Recurrent/Metastatic SCCHN
The Nurse View.
Evolving Paradigms in the Management of HR-Positive Breast Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.
Perspectives on Triple-Negative Breast Cancer
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
Optimizing Use of Biological Agents in Ulcerative Colitis
New Patient Journeys in Non-small cell lung cancer
Progression After Cancer Immunotherapy in Advanced NSCLC
سرطان الثدي Breast Cancer
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.
Moving Evidence into Practice: Breast Cancer Highlights From Chicago
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
CDK4/6 Inhibitors in Breast Cancer:
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
CDK4/6 Inhibitors in Practice
Optimizing Management of Advanced Bladder Cancer
Managing gBRCA-Positive Metastatic Breast Cancer
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
Treatment of HR+ Breast Cancer: A Clinical Update
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Hormone Receptor-Positive Advanced Breast Cancer:
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Examining the Latest Evidence in PAH
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Advancing the Treatment of IBD With Biologics
Treating CD30-Expressing Cutaneous T-Cell Lymphoma
The Road to Quality Improvement in HER2-Positive Breast Cancer
Hormone Receptor-Positive Advanced Breast Cancer Introduction
Introduction Advanced Hormone Receptor-Positive Breast Cancer
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Are We Making Progress in the Management of Huntington Disease?
New Paradigms in HR-Positive Advanced Breast Cancer
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
From Adjuvant to Metastatic in Melanoma
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Clinical Challenges in the Patient With Relapsed Multiple Myeloma
CDK4/6 Inhibitors.
PAH Pathways: What Do the Data Tell Us?”
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Championing Evidence-Based Care in Patients With Acute Low Back Pain
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
A Closer Look.
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Identifying TRK Fusions in Head and Neck Cancer
Miquel Àngel Seguí Palmer ¿Ciclinas para todas?
Recent Developments in the Treatment of Advanced and Metastatic RCC
The Power of As-Treated Analyses
Presentation transcript:

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Faculty

Introduction

Introduction (cont)

Treatment in the First-Line Setting

Clinical Case 1: Postmenopausal Woman

Clinical Case 1: First-Line Treatment

Clinical Case 1: Disease Progression

Case 1: How Would You Treat?

Case 1: Treatment Discussion

FALCON: Study Design

FALCON: Results

FALCON Subset Analysis: Fulvestrant in Patients With Nonvisceral Disease[a,b]

Implications for Patients

Case 1a: Alternate Scenario

Case 1a: Inclusion Criteria for Metastatic Breast Cancer Studies

Case 1a: Treatment Discussion

PALOMA-2 and MONALEESA-2: Results

PALOMA-2 and MONALEESA-2: Safety

Case 1b: Alternate Scenario

Case 1b: Alternate Scenario (cont)

Case 1b: Treatment Discussion

Case 1b: Treatment Discussion (cont)

Case 1b: Treatment Discussion (cont)

Treatment in the Second-Line Setting

Treatment in the Second-Line Setting

Treatment in the Second-Line Setting (cont)

Treatment in the Second-Line Setting (cont)

Conclusions

Abbreviations

Abbreviations (cont)